Hyrax Biosciences
Cape Town, South Africa· Est.
Cloud‑based NGS analysis platform delivering rapid, disease‑agnostic genomics insights for labs and pharma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Cloud‑based NGS analysis platform delivering rapid, disease‑agnostic genomics insights for labs and pharma.
Infectious DiseasesOncology
Technology Platform
Exatype is a cloud‑native NGS analysis suite that automates QC, mapping, variant calling and interpretation using proprietary algorithms, with modular disease‑specific plug‑ins.
Opportunities
Expansion into emerging markets, addition of AI‑driven interpretation, and regulatory clearance for diagnostic modules could drive rapid adoption.
Risk Factors
Reliance on cloud infrastructure, competitive pressure from established NGS platforms, and the need for continuous regulatory compliance pose significant challenges.
Competitive Landscape
Competes with Illumina BaseSpace, DNAnexus, and Seven Bridges; differentiates through disease‑agnostic plug‑ins, African market focus, and HIPAA‑compliant cloud security.